Dr. Bruce Johnson, MD

Medical Oncology Boston, MA Male
NPI: 1578523866
Total Payments
$134,704
2024 Payments
$16,358
Companies
17
Transactions
108
Medicare Patients
333
Medicare Billing
$58,641

Payment Breakdown by Category

Consulting$83,571 (62.0%)
Research$29,130 (21.6%)
Travel$14,409 (10.7%)
Other$5,911 (4.4%)
Food & Beverage$1,683 (1.2%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $83,571 34 62.0%
Unspecified $29,130 30 21.6%
Travel and Lodging $14,409 20 10.7%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,961 5 2.9%
Honoraria $1,950 1 1.4%
Food and Beverage $1,683 18 1.2%

Payments by Type

General
$105,574
78 transactions
Research
$29,130
30 transactions

Top Paying Companies

Company Total Records Latest Year
Daiichi Sankyo Inc. $26,250 21 $0 (2022)
Novartis Pharmaceuticals Corporation $21,536 13 $0 (2024)
F. Hoffmann-La Roche AG $14,674 20 $0 (2024)
Novartis Pharma AG $14,551 7 $0 (2019)
PFIZER INC. $14,400 12 $0 (2024)
Eli Lilly and Company $8,567 2 $0 (2020)
JAZZ PHARMACEUTICALS INC. $7,495 3 $0 (2023)
Chugai Pharmaceutical Co., Ltd. $6,997 6 $0 (2024)
Foundation Medicine, Inc. $5,280 5 $0 (2019)
Genentech, Inc. $4,748 5 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $16,358 18 PFIZER INC. ($6,070)
2023 $13,363 9 PFIZER INC. ($4,470)
2022 $22,668 16 Daiichi Sankyo Inc. ($11,816)
2021 $17,756 17 Janssen Scientific Affairs, LLC ($4,040)
2020 $31,009 17 Daiichi Sankyo Inc. ($12,378)
2019 $28,421 22 Novartis Pharma AG ($14,551)
2018 $2,540 5 Novartis Pharmaceuticals Corporation ($1,859)
2017 $2,589 4 Novartis Pharmaceuticals Corporation ($2,487)

All Payment Transactions

108 individual payment records from CMS Open Payments — Page 1 of 5

Date Company Product Nature Form Amount Type
12/20/2024 PFIZER INC. BRAFTOVI (Drug), VIZIMPRO, LORBRENA — In-kind items and services $3,200.00 Research
Study: BRAFTOVI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY
11/14/2024 AstraZeneca UK Limited — Consulting Fee Cash or cash equivalent $1,712.50 General
11/14/2024 AstraZeneca UK Limited — Travel and Lodging Cash or cash equivalent $96.00 General
11/14/2024 AstraZeneca UK Limited — Travel and Lodging Cash or cash equivalent $26.80 General
09/30/2024 F. Hoffmann-La Roche AG Tecentriq (Biological) — In-kind items and services $365.91 Research
Study: LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC • Category: BioOncology
09/14/2024 PFIZER INC. XALKORI (Drug), MEKTOVI — In-kind items and services $940.00 Research
Study: XALKORI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY
09/10/2024 PFIZER INC. XALKORI (Drug), MEKTOVI — In-kind items and services $940.00 Research
Study: XALKORI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY
08/12/2024 Chugai Pharmaceutical Co., Ltd. Tecentriq (Biological) Consulting Fee Cash or cash equivalent $1,900.00 General
Category: BioOncology
08/12/2024 Chugai Pharmaceutical Co., Ltd. Tecentriq (Biological) Travel and Lodging Cash or cash equivalent $796.31 General
Category: BioOncology
08/12/2024 Chugai Pharmaceutical Co., Ltd. Tecentriq (Biological) Travel and Lodging Cash or cash equivalent $165.45 General
Category: BioOncology
08/07/2024 PFIZER INC. — — In-kind items and services $330.00 Research
Study: DACOMITINIB CLINICAL PUBLICATION PROGRAM
06/30/2024 F. Hoffmann-La Roche AG Tecentriq (Biological) — In-kind items and services $715.76 Research
Study: LCMC3 • Category: BioOncology
05/03/2024 PFIZER INC. LORBRENA (Drug), XALKORI, MEKTOVI — In-kind items and services $330.00 Research
Study: LORLATINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY
04/10/2024 Novartis Pharmaceuticals Corporation — — Cash or cash equivalent $2,282.64 Research
Study: CACZ885U2301-CANOPY-1 ; CACZ885V2201C-CANOPY-H
04/03/2024 PFIZER INC. LORBRENA (Drug), XALKORI, MEKTOVI — In-kind items and services $330.00 Research
Study: LORLATINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY
03/22/2024 Janssen Global Services, LLC RYBREVANT (Drug) Consulting Fee Cash or cash equivalent $2,025.00 General
Category: Oncology
02/22/2024 Janssen Global Services, LLC RYBREVANT (Drug) Food and Beverage In-kind items and services $159.75 General
Category: Oncology
02/21/2024 Genentech, Inc. Tecentriq (Biological) Food and Beverage In-kind items and services $41.84 General
Category: BioOncology
06/30/2023 F. Hoffmann-La Roche AG Alecensa (Biological) — In-kind items and services $543.79 Research
Study: NAUTIKA1 previously LCMC4 • Category: BioOncology
06/30/2023 F. Hoffmann-La Roche AG Tecentriq (Biological) — In-kind items and services $258.35 Research
Study: LCMC3 • Category: BioOncology
05/15/2023 PFIZER INC. — — In-kind items and services $940.00 Research
Study: ENCORAFENIB CLINICAL PUBLICATION PROGRAM
04/07/2023 PFIZER INC. — — In-kind items and services $3,200.00 Research
Study: ENCORAFENIB CLINICAL PUBLICATION PROGRAM
03/31/2023 F. Hoffmann-La Roche AG Tecentriq (Biological) — In-kind items and services $1,370.41 Research
Study: LCMC3 • Category: BioOncology
03/31/2023 F. Hoffmann-La Roche AG Tecentriq (Biological) — In-kind items and services $715.76 Research
Study: LCMC3 • Category: BioOncology
03/10/2023 JAZZ PHARMACEUTICALS INC. JZP-815 Consulting Fee Cash or cash equivalent $3,200.00 General
123…5»

Research Studies & Clinical Trials

Study Name Company Amount Records
A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC F. Hoffmann-La Roche AG $4,412 5
ENCORAFENIB CLINICAL PUBLICATION PROGRAM PFIZER INC. $4,140 2
LCMC3 F. Hoffmann-La Roche AG $4,107 6
LUNG ONCOLOGY CLINICAL PUBLICATION PROGRAM PFIZER INC. $3,530 2
BRAFTOVI CLINICAL PUBLICATION PROGRAM PFIZER INC. $3,200 1
CACZ885U2301-CANOPY-1 ; CACZ885V2201C-CANOPY-H Novartis Pharmaceuticals Corporation $2,283 1
XALKORI CLINICAL PUBLICATION PROGRAM PFIZER INC. $1,880 2
RESEARCH RELATED PUBLICATION SUPPORT NOVARTIS PHARMACEUTICALS CORPORATION $1,735 2
Phase II Study of TKIs as Neoadjuvant Therapy in Stage I-III Resectable NSCLC with ALK, ROS1, NTRK, or BRAFV600 Alterations F. Hoffmann-La Roche AG $1,141 1
LORLATINIB CLINICAL PUBLICATION PROGRAM PFIZER INC. $990.00 3
NAUTIKA1 previously LCMC4 F. Hoffmann-La Roche AG $543.79 1
LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC F. Hoffmann-La Roche AG $365.91 1
DACOMITINIB CLINICAL PUBLICATION PROGRAM PFIZER INC. $330.00 1
ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM PFIZER INC. $330.00 1
PHASE II STUDY OF TKIS AS NEOADJUVANT THERAPY IN STAGE II III RESECTABLE NSCLC WITH ALK, ROS1, NTRK OR BRAF V600 ALTERATIONS F. Hoffmann-La Roche AG $143.00 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 3 86 139 $68,753 $12,950
2022 2 77 136 $64,712 $12,719
2021 2 80 192 $70,202 $16,564
2020 4 90 218 $67,166 $16,408
Total Patients
333
Total Services
685
Medicare Billing
$58,641
Procedure Codes
15

All Medicare Procedures & Services

15 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 32 56 $22,993 $4,584 19.9%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 27 52 $21,231 $4,149 19.5%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2023 14 18 $13,100 $2,206 16.8%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2023 13 13 $11,429 $2,011 17.6%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 26 52 $20,800 $4,390 21.1%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 25 51 $20,393 $4,234 20.8%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 15 19 $13,537 $2,402 17.7%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 11 14 $9,982 $1,693 17.0%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 43 97 $32,703 $7,660 23.4%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 23 75 $25,125 $6,460 25.7%
99215 Established patient outpatient visit, total time 40-54 minutes Facility 2021 14 20 $12,374 $2,443 19.7%
99214 Established patient office or other outpatient, visit typically 25 minutes Facility 2020 50 161 $43,807 $10,864 24.8%
99215 Established patient office or other outpatient, visit typically 40 minutes Facility 2020 13 21 $10,125 $2,066 20.4%
99205 New patient office or other outpatient visit, typically 60 minutes Facility 2020 14 14 $8,280 $1,943 23.5%
99443 Physician telephone patient service, 21-30 minutes of medical discussion Facility 2020 13 22 $4,954 $1,535 31.0%

About Dr. Bruce Johnson, MD

Dr. Bruce Johnson, MD is a Medical Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578523866.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Johnson, MD has received a total of $134,704 in payments from pharmaceutical and medical device companies, with $16,358 received in 2024. These payments were reported across 108 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($83,571).

As a Medicare-enrolled provider, Johnson has provided services to 333 Medicare beneficiaries, totaling 685 services with total Medicare billing of $58,641. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.

Practice Information

  • Specialty Medical Oncology
  • Location Boston, MA
  • Active Since 03/23/2006
  • Last Updated 12/07/2011
  • Taxonomy Code 207RX0202X
  • Entity Type Individual
  • NPI Number 1578523866

Products in Payments

  • CANAKINUMAB_ILARIS_IMMUNOLOGY (Biological) $14,551
  • ENHERTU (Drug) $11,816
  • TECENTRIQ (Biological) $8,373
  • Tecentriq (Biological) $7,377
  • ILARIS (Biological) $5,900
  • FOUNDATIONACT (Device) $5,280
  • Alecensa (Biological) $4,633
  • Non-Covered Product (Drug) $4,135
  • PIQRAY (Drug) $4,125
  • BRAFTOVI (Drug) $3,530
  • JZP-815 $3,200
  • ZYKADIA (Drug) $2,487
  • RYBREVANT (Drug) $2,185
  • Enhertu (Drug) $2,055
  • COSELA (Drug) $1,950
  • XALKORI (Drug) $1,880
  • TAFINLAR (Drug) $1,735
  • LORBRENA (Drug) $990.00
  • MEKINIST (Drug) $264.78
  • FARXIGA (Drug) $16.07

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Medical Oncology Doctors in Boston

Dr. George Demetri, Md, MD

Medical Oncology — Payments: $1.6M

Medical Oncology $1.6M

Pasi Antero Janne, Md Phd, MD PHD

Medical Oncology — Payments: $1.1M

Medical Oncology $1.1M

Dr. Praful Ravi, Mb Bchir, MB BCHIR

Medical Oncology — Payments: $921,658

Medical Oncology $921,658

Dr. Alicia Morgans, Md, MD

Medical Oncology — Payments: $755,277

Medical Oncology $755,277

Dr. Erica Mayer, Md Mph, MD MPH

Medical Oncology — Payments: $665,160

Medical Oncology $665,160

Dr. Joaquin Bellmunt Molins, M.d, M.D

Medical Oncology — Payments: $610,701

Medical Oncology $610,701